MHC-HE446-100μg / 询价
MHC-HE446-500μg / 询价
MHC-HE446-500μgx2 / 询价
- 关联产品
- 客服电话
- 技术支持
Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein
Recombinant Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and SLLMWITQC peptide [Accession | A0A140T913(HLA-A*02:01)&P61769(B2M)&SLLMWITQC].
The protein has a predicted MW of 35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) same as Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Supplied as 0.22μm filtered solution in 20mM Tris, 150mM NaCl (pH 8.0).
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
MHC; MY-ESO-1; CT6.1; LAGE-2; CTAG1; CTAG1B; ESO1CTAG; LAGE2A; NY-ESO-1; CTAG1A
(1)Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. PMID: 29770138; PMCID: PMC5941317.
